A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome
John Liddle, Véronique Bénéton, Matthew A. Benson, Ryan P. Bingham, Anne Bouillot, Anne-Bénédicte Boullay, Eloisa I. Brook, Jenni Cryan, Alexis Denis, Emma V. Edgar, Alan Ferrie, Marie-Hélène Fouchet, Didier Grillot, Duncan S. Holmes, Ashleigh Howes, Gaël Krysa, Alain Laroze, Mark Lennon, Fiona McClure, Alexandre Moquette, Edwige Nicodème, Brandon G. Santiago, Leandro L. Santos, Kathrine J. Smith, James H. Thorpe, Gary Thripp, Lionel Trottet, Ann L. Walker, Simon A. Ward, Yichen Wang, Steve Wilson, Andrew C. Pearce, Alain Hovnanian
Topics & Concepts
KallikreinSerine proteaseStratum corneumPharmacologyBiologyProtease inhibitor (pharmacology)ImmunologyProteaseBiochemistryEnzymeHuman immunodeficiency virus (HIV)Viral loadAntiretroviral therapyGeneticsSkin and Cellular Biology ResearchContact Dermatitis and AllergiesNail Diseases and Treatments